Arcturus Therapeutics Holdings (ARCT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Arcturus Therapeutics Holdings

NasdaqGM•Healthcare•Biotechnology

$14.14-0.60(-0.04%)Market open

Market Cap

$418.96M

P/S

14.3x

P/B

2.4x

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

How this company scores

WeakMetricSide Score: 34/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (2/25).

Profitability11/25

Growth2/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Long cash runwayInterest easily coveredNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 0.0x5y range 0.0x – 48.1x

Currently near its 4-quarter median.

P/S · 14.3x5y range 0.0x – 139.9x

Currently above its 20-quarter median.

P/B · 2.4x5y range 0.0x – 4.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $418.96M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $29.37M
Q. Revenue: $2.96M
TTM EBITDA: $-99.61M
TTM Op. Income: $-102.29M
Q. Op. Income: $-25.55M
TTM Net Income: $-93.28M
Q. Net Income: $-23.79M
EPS: $-0.84
Shares Out.: $28.42M

$29.37M in TTM revenue declined 76.0% YoY, reaching $2.96M last quarter. TTM EBITDA of $-99.61M and TTM operating income of $-102.29M show growth is flowing through to the bottom line. However, net income is negative at $93.28M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 7 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -843.0%
Op. Margin: -863.3%
Net Margin: -803.8%

Op. margin of -863.3% is down 822.3% YoY — costs are rising relative to revenue. Net margin at -803.8% Over the past year, operating margin is down 2003% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 14.3x
P/B Ratio: 2.4x

P/S of 14.3x and P/B of 2.4x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $224.31M
Cash: $191.48M
Long-Term Debt: N/A
Book Value: $171.81M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-19.91M
TTM Free Cash Flow: $-72.82M
FCF Margin: -248.0%
FCF / Net Income: 0.8

TTM FCF of $-72.82M on $-19.91M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 12% — a weakening trend.